The Cuban Ministry of Public Health invites you to participate in person or virtually in the V International Convention “Cuba Salud 2025” ( Cuba Health 2025), in Havana, from April 21 to 25, 2025. In parallel, the XVI “Health for All” Trade Fair and the II Medical Tourism and Wellness Fair will be held.
“Cuba Health 2025” is sponsored by prestigious national and international organizations. Its purposes include discussing public health management models in the post-Covid-19 stage, at the global, regional and local levels. Emphasis will be placed on the adoption of policies that contribute to consolidating the “ONE HEALTH” paradigm as a comprehensive health strategy.
“Cuba Health 2025” includes congresses, symposia, workshops and scientific meetings on health informatics, medical education in the 20th century, hygiene and epidemiology, primary care and nanosciences and nuclear technologies. Also on health and disasters, oral health, maternal and child health, rehabilitation, science and innovation in health, regulatory systems for medicines and medical devices, communication, etc. Visit the Events Section of this Convention to learn about the sub-themes of these topics.
Cuba-Health 2022 had more than 2,000 in-person participants from 65 countries, including 44 high-level delegations, among them about 20 Ministers. The 15th Health for All 2022 Trade Fair was attended by 118 companies from 40 countries and 68 Cuban firms, and 16 new contracts and commercial agreements were signed for more than 45 million USD.
“Cuba Salud 2025” is an opportunity to share the experiences of your country and learn about those of other countries in different areas of health, including the Cuban system with some indicators similar to those of developed countries.
It is also a good opportunity to learn the secrets of the quality of doctors graduated in Cuba. That is why in 2024 the Latin American School of Medicine (ELAM) of Cuba and its program were internationally accredited for 6 years by the Union of Universities of Latin America and the Caribbean (UDUALC).
Since its foundation in 1999, 25 years ago, ELAM has graduated 30,878 doctors and stomatologists from 122 countries, including Mongolia and more than 250 from the United States.
The XVI “Health for All” Trade Fair (XVI Salud Para Todos) is a window to learn about new medicines and technologies from the world and from BIOCUBAFARMA, the Group of Biotechnology and Pharmaceutical Industries of Cuba.
BioCubaFarma exports to more than 40 countries; has more than 2,000 patents granted in other countries, including more than 100 in the US, and complies with Good Manufacturing Practices standards.
BioCubaFarma produces generic and other biotechnology drugs, single, trivalent, tetravalent and pentavalent vaccines, 198 reagents and diagnostic kits and the automated equipment for them. It also manufactures about 80 medical devices and technologies, including digital electrocardiographs, patient monitors for therapy rooms, lung ventilators and glucometers. It also produces ambulatory blood pressure monitors and maternal-fetal monitors, portable digital electroencephalographs, automated electroaudiometers, etc.
BioCubaFarma also has about 15 companies of its own or joint ventures in other countries, including in Asia: 5 in China, 1 in Thailand, 1 in Singapore, 2 in Spain, 1 in Germany, 1 in the United Kingdom (UK) and 4 in Latin America.
Among the Cuban biopharmaceuticals patented in the US is Heberprot-P, registered in Mongolia, a unique product in the world that can prevent amputations due to diabetic foot ulcers.
The Cuban therapeutic vaccine CIMAvax-EGF for lung cancer was the first Cuban biopharmaceutical to obtain authorization from the US drug regulator to conduct clinical trials in that country.
Nimotuzumab: a humanized anti-EGFR antibody, registered in more than 20 countries and with more than 500,000 patients treated, is part of the list of essential medicines in Cuba, China and India, among others. It is effective for the treatment of advanced carcinomas of the esophagus, pancreas and non-small cell lung, high-grade glioma (adult and pediatric) and pediatric brain tumor.
It is no coincidence that since 1989, nine Cuban inventions, most of them from BioCubaFarma, have received the Gold Medal of the World Intellectual Property Organization (WIPO).
Cuba developed the world's first vaccine against meningococcal disease B, which received a WIPO Gold Medal in 1989 and is licensed in more than 17 countries such as Brazil, Colombia and Vietnam.
The world's first synthetic vaccine (Quimi-Hib) against Haemophilus influenzae type b (or Hib) - WIPO Gold Medal 2005 - was patented by the Universities of Havana and Ottawa, Canada. Quimi-Hib is used for the prophylaxis of pneumonia and meningitis.
The Cuban recombinant vaccine against hepatitis B has received prequalification from the World Health Organization (WHO) for international use since 2001 and is exported to more than 30 countries.
In 2021, Cuba also developed three effective vaccines against Covid-19, the only ones designed in Latin America and the Caribbean with an effectiveness of more than 90%.
One of BioCubaFarma's latest developments is NeuroEpo, registered in Cuba in 2022, for the effective treatment of mild and moderate Alzheimer's, which improves or stabilizes cognitive decline in more than 80% of patients.
Presentations and conferences must be submitted by February 21, 2025. For more information, registration, etc., visit: https://cubasalud.sld.cu/evento/11 or www.convenciónsalud2025.sld.cu
If you live in Mongolia, contact the Cuban Embassy in Ulaanbaatar: embajada@mn.embacuba.cu. If you live in another country, kindly contact the Cuban Embassy or Consulate in your country of residence.
